Patents by Inventor Leonard Smith

Leonard Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7081529
    Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: July 25, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
  • Publication number: 20060141572
    Abstract: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 29, 2006
    Inventors: Leonard Smith, Melody Jensen
  • Patent number: 7049296
    Abstract: Urea derivatives of formula I are disclosed: The compounds are inhibitors of ?-secretase, and hence useful in the treatment or prevention of Alzheimer's Disease
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: May 23, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Adrian Leonard Smith, Graeme Irvine Stevenson
  • Patent number: 7037680
    Abstract: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: May 2, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Leonard A. Smith, Melody Jensen
  • Publication number: 20050040177
    Abstract: The present invention provides a container for dispensing individual paper products that includes a housing, a cover hingedly or removably attached to the housing wherein the cover defines a dispensing opening, a means for elevating paper products, and a plunger disposed in the interior area of the housing. The plunger is urged toward the dispensing opening by the means for elevating paper products. The container may be included in a system for dispensing paper products that further includes a cartridge containing paper products. The cartridge defines a dispensing opening and a second opening wherein the means for elevating paper products extends through the second opening into the interior area of the cartridge to contact the paper products and urge the paper products toward the dispensing opening. The cartridge and container may be configured wherein the second opening is formed by removal of a removable portion during the process of inserting the cartridge into the container.
    Type: Application
    Filed: October 3, 2003
    Publication date: February 24, 2005
    Inventors: Paul Tramontina, Suzanne Hamlin, Frances Mayfield, Leonard Smith, Martin Vozar
  • Publication number: 20040073116
    Abstract: This invention relates to a method of automatically setting the gain of an echo signal in a Doppler ultrasound haemodynamic monitor. In essence the invention comprises monitoring the strength of velocity components measured by the apparatus, and identifying a group of such components occupying a particular band within the overall velocity spectrum. The signal gain is then adjusted so that the perceived with of the band falls within predetermined limits. The monitoring or assessment of the velocity components is preferably undertaken when the overall flow velocity is high e.g. during systole.
    Type: Application
    Filed: November 6, 2003
    Publication date: April 15, 2004
    Inventor: Leonard Smith
  • Publication number: 20040029862
    Abstract: A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.
    Type: Application
    Filed: February 5, 2003
    Publication date: February 12, 2004
    Inventors: Patrice Charles Belanger, Ian James Collins, Joanne Claire Hannam, Timothy Harrison, Stephen John Lewis, Andrew Madin, Edward Giles McIver, Alan John Nadin, Joseph George Neduvelil, Mark Steven Shearman, Adrian Leonard Smith, Timothy Jason Sparey, Graeme Irvine Stevenson, Martin Richard Teall
  • Patent number: 6670148
    Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: December 30, 2003
    Assignee: BioTherapeutics, Inc.
    Inventors: David D. Mundschenk, Leonard A. Smith
  • Publication number: 20030215437
    Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.
    Type: Application
    Filed: November 7, 2002
    Publication date: November 20, 2003
    Inventors: David D. Mundschenk, Leonard A. Smith
  • Patent number: 6647887
    Abstract: A linear ignition fuze has a sheath, the inner surface of which has an irregular cross section such that the sheath is capable of forming a gas channel against a single strand core having a substantially circular (e.g. circular or elliptical) cross section. According to one embodiment of the invention, the sheath wall is of a non-uniform thickness having a cylindrical outer surface and a polygonal inner surface. The gap formed between the apexes of the polygonal inner surface and the substantially cylindrical core form the gas channels, while the contact between the side walls of the polygonal inner surface and the cylindrical core confine the core within the sheath.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: November 18, 2003
    Assignee: Universal Propulsion Company, Inc.
    Inventors: Leonard Smith, Gregory B. Dougherty, Michael H. Tolson, David L. Harrington
  • Patent number: 6645149
    Abstract: The invention provides an ultrasound probe for use in a Doppler ultrasound haemodynamic monitor having a host signal processor and an interconnect cable. The probe includes a memory device, preferable in the form of E 2PROM which communicates with the host processor to limit the life of the probe and to render the probe inoperable in the event an attempt is made to use the probe in conjunction with more than one patient.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: November 11, 2003
    Assignee: Deltex (Guernsey) Limited
    Inventor: Leonard Smith
  • Publication number: 20030055005
    Abstract: 1 Novel urea derivatives of formula I are disclosed: The compounds are inhibitors of &ggr;-secretase, and hence useful in the treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: August 23, 2002
    Publication date: March 20, 2003
    Inventors: Jose Luis Castro Pineiro, Adrian Leonard Smith, Graeme Irvine Stevenson
  • Publication number: 20030009025
    Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.
    Type: Application
    Filed: July 20, 2001
    Publication date: January 9, 2003
    Inventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
  • Publication number: 20020189481
    Abstract: A linear ignition fuze has a sheath, the inner surface of which has an irregular cross section such that the sheath is capable of forming a gas channel against a single strand core having a substantially circular (e.g. circular or elliptical) cross section. According to one embodiment of the invention, the sheath wall is of a non-uniform thickness having a cylindrical outer surface and a polygonal inner surface. The gap formed between the apexes of the polygonal inner surface and the substantially cylindrical core form the gas channels, while the contact between the side walls of the polygonal inner surface and the cylindrical core confine the core within the sheath.
    Type: Application
    Filed: May 29, 2002
    Publication date: December 19, 2002
    Applicant: GOODRICH COMPANY
    Inventors: Leonard Smith, Gregory B. Dougherty, Michael H. Tolson, David L. Harrington
  • Patent number: 6495143
    Abstract: Using the nontoxic heavy chain fragment from botulinum neurotoxins A-G, compositions and methods of use in inducing an immune response which is protective against intoxication with botulinum in subjects is described.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 17, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: John S. Lee, Peter Pushko, Jonathan F. Smith, Michael Parker, Mark T. Dertzbaugh, Leonard Smith
  • Patent number: 6486153
    Abstract: A class of tryptamine analogues bearing an optionally substituted phenyl nucleus at the 2-position are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse neurological conditions, including psychotic disorders such as schizophrenia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Steven Michael Hutchins, Stephen John Lewis, Michael Rowley, Adrian Leonard Smith, Graeme Irvine Stevenson
  • Publication number: 20020168727
    Abstract: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A.
    Type: Application
    Filed: November 6, 2001
    Publication date: November 14, 2002
    Inventors: Leonard Smith, Melody Jensen
  • Publication number: 20020068317
    Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.
    Type: Application
    Filed: August 5, 1999
    Publication date: June 6, 2002
    Inventors: DAVID D. MUNDSCHENK, LEONARD A. SMITH
  • Publication number: 20020034521
    Abstract: Using the nontoxic heavy chain fragment from botulinum neurotoxins A-G, compositions and methods of use in inducing an immune response which is protective against intoxication with botulinum in subjects is described.
    Type: Application
    Filed: July 9, 1999
    Publication date: March 21, 2002
    Inventors: JOHN SCOTT LEE, PETER PUSHKO, JONATHAN F. SMITH, MICHAEL PARKER, MARK T. DERTZBAUGH, LEONARD SMITH
  • Patent number: 6264477
    Abstract: A photolithographically patterned spring contact is formed on a substrate and electrically connects contact pads on two devices. The spring contact also compensates for thermal and mechanical variations and other environmental factors. An inherent stress gradient in the spring contact causes a free portion of the spring contact to bend up and away from the substrate. An anchor portion remains fixed to the substrate and is electrically connected to a first contact pad on the substrate. The spring contact is made of an elastic material and the free portion compliantly contacts a second contact pad, thereby electrically interconnecting the two contact pads. The free portion is initially fixed to the substrate to intentionally form the inherent stress gradient in the elastic member. The free portion is released from the substrate by etching a release layer deposited on the substrate so the inherent stress gradient in the elastic member biases the free portion away from the substrate.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: July 24, 2001
    Assignee: Xerox Corporation
    Inventors: Donald Leonard Smith, Andrew Sebastian Alimonda